ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 590

Microvesicles in the Lungs of Early Rheumatoid Arthritis

Vijay Joshua1, Fariborz Mobarrez1, Gudrun Reynisdottir1, Johan Öckinger2, Jan Wahlström2, Johan Grunewald2, Heidi Wähämaa1 and Anca I Catrina1, 1Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, 2Division of Respiratory Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: ACPA, lung and microparticles

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Structural changes, increased tissue citrullination and signs of local inflammation are present in the pulmonary compartment of early seropositive RA and seropositive individuals at risk for developing RA. Cell-derived Microvesicles (MVs) are small particles (0.1-1.0 microns), formed by the outward blebbing of the plasma cell membrane, that can be released during and further contribute to inflammation. The MVs express surface markers similar to the cell of origin and have previously shown to induce tissue injury in the lung. We aimed to study the role of MVs in the lungs of early RA.

Methods: Bronchoalveolar lavage (BAL) fluid was obtained from 20 RA patients (8 females, 12 males, 16 sero-positive and 4 sero-negative, 9 smokers and 11 non-smoker, 59 median age). Additionally BAL samples from disease controls (10 patients with sarcoidosis with active lung inflammation) and healthy volunteers (n=3) were collected. Microvesicles derived from macrophage, endothelial cells, lymphocytes and T-cells were analysed by flow cytometry for phosphatidylserine, CD45, CD63E, CD68, CD154 and CD163 expression. Anti citrullinated protein antibodies (ACPA) were purified from the peripheral blood of RA patients by affinity chromatography, fluorescent labeled and used to identify expression of citrullinated proteins in MVs using flow cytometry.

Results: Elevated numbers of total MVs were observed in the BAL of RA (Mean±SD, 526.2±291.7, events/μL) compared with disease controls (402.3±107.5, p>0.05) and healthy volunteers (283.0±52.8, p<0.05). MVs derived from macrophage, endothelial cell and lymphocytes were significant increased in the BAL of RA patients (27.2± 13.4, events/μL for macrophage derived MVs, 20.8±9.0 for endothelial derived MVs and 47.7±24.4 for lymphocytes derived MVs) as compared to both disease controls (16.1±6.0 for macrophage derived MVs, 12.3±3.6 for endothelial derived MVs and 25.1±11.9 for lymphocytes derived MVs) and healthy volunteers (5.9±1.9 for macrophage derived MVs, 10.1±2.9 for endothelial derived MVs and 8.1±5.0 for lymphocytes derived MVs), (p<0.05 for all comparisons). Citrulline containing MVs, detected by ACPA were significantly higher in RA compared to disease controls (6.6±2.7 vs 4.3±1.1, p<0.05) and healthy BAL (6.6±2.7 vs 3.3±1.4, p<0.05) whereas no such difference and significantly lower amount of MVs were detected using RA-derived IgGs others than ACPA as controls.

Conclusion: MVs and citrulline-containing MVs are present in the RA BAL in a higher proportion than in the BAL of either patient with inflammatory lung disease (sarcoidosis) and healthy controls, suggesting a role for MVs in RA-associated lung changes. Confirmation of current findings in larger samples and investigation of potential pathogenic effects of MVs are needed.


Disclosure: V. Joshua, None; F. Mobarrez, None; G. Reynisdottir, None; J. Öckinger, None; J. Wahlström, None; J. Grunewald, None; H. Wähämaa, None; A. I. Catrina, None.

To cite this abstract in AMA style:

Joshua V, Mobarrez F, Reynisdottir G, Öckinger J, Wahlström J, Grunewald J, Wähämaa H, Catrina AI. Microvesicles in the Lungs of Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/microvesicles-in-the-lungs-of-early-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/microvesicles-in-the-lungs-of-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology